07-1437
Anti-PDGF-BB Antibody
from rabbit, purified by affinity chromatography
Sinonimo/i:
Platelet-derived growth factor B chain precursor, Platelet-derived growth factor beta polypeptide, Platelet-derived growth factor, beta polypeptide (oncogene SIS), oncogene SIS, Platelet-derived growth factor, Platelet-derived growth factor beta, Platele
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
About This Item
Codice UNSPSC:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Prodotti consigliati
Origine biologica
rabbit
Livello qualitativo
Forma dell’anticorpo
affinity purified immunoglobulin
Tipo di anticorpo
primary antibodies
Clone
polyclonal
Purificato mediante
affinity chromatography
Reattività contro le specie
human
tecniche
ELISA: suitable
neutralization: suitable
western blot: suitable
Isotipo
IgG
N° accesso NCBI
N° accesso UniProt
Condizioni di spedizione
dry ice
modifica post-traduzionali bersaglio
unmodified
Informazioni sul gene
human ... PDGFB(5155)
Descrizione generale
Platelet-Derived Growth Factor (PDGF) is a dimer of A (17 kDa) and B (14 kDa) chains (AA, AB, or BB). Its receptors are transmembrane receptor tyrosine kinases, PDGF Receptors type A and B. The type A PDGF receptor binds all three PDGFs with high affinity, whereas the type B PDGF receptor is selective for PDGF-BB. PDGF signals as a growth and survival factor, as it is a potent activator of the PI3 Kinase pathway. PDGF signaling appears to play an essential role in the development of tumors of glial origin.
Specificità
Reacts with human PDGF-BB.
Immunogeno
Highly purified (>98%) recombinant human PDGF-BB
Applicazioni
Anti-PDGF-BB Antibody detects level of PDGF-BB & has been published & validated for use in WB, ELISA, NEUT.
ELISA: 0.5 μg/mL dilution of a previous lot will allow detection (in direct ELISA) of
0.2-0.4 ng/well when human PDGF-BB is used to coat the plate.
Neutralization: To yield ½ maximal inhibition (ND50) of the biological activity of hPDGF-BB (2.5
ng/mL), a concentration of 0.03-0.04 μg/mL of a previous lot of this antibody was required.
Immunohistochemistry(paraffin): Anti-IGF-1R, representative staining-pattern and morphology on ductal breast carcinoma. Tissue was pretreated with EDTA, pH 8.0 for Epitope retrieval. A previous lot of this antibody was diluted to 1:200 (RT incubation), using IHC-Select Detection with HRP-DAB.
Optimal working dilutions must be determined by the end user.
0.2-0.4 ng/well when human PDGF-BB is used to coat the plate.
Neutralization: To yield ½ maximal inhibition (ND50) of the biological activity of hPDGF-BB (2.5
ng/mL), a concentration of 0.03-0.04 μg/mL of a previous lot of this antibody was required.
Immunohistochemistry(paraffin): Anti-IGF-1R, representative staining-pattern and morphology on ductal breast carcinoma. Tissue was pretreated with EDTA, pH 8.0 for Epitope retrieval. A previous lot of this antibody was diluted to 1:200 (RT incubation), using IHC-Select Detection with HRP-DAB.
Optimal working dilutions must be determined by the end user.
Research Category
Signaling
Signaling
Research Sub Category
Growth Factors & Receptors
Growth Factors & Receptors
Qualità
Routinely evaluated by Western Blot on Huvec lysates.
Western Blot Analysis:
1:500 dilution of this lot detected PDGF-BB on 10 μg of Huvec lysates.
Western Blot Analysis:
1:500 dilution of this lot detected PDGF-BB on 10 μg of Huvec lysates.
Descrizione del bersaglio
28 kDa
Linkage
Replaces: AB1487P
Stato fisico
Affinity purified
Purified rabbit polyclonal IgG lyophilized from 0.5X PBS, pH 7.4. Reconstitute with sterile distilled water.
Stoccaggio e stabilità
Maintain lyophilized material desiccated below 0°C. After reconstitution maintain at -20°C in convenient undiluted aliquots for up to 6 months from date of receipt.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Esclusione di responsabilità
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Motore di ricerca dei prodotti.
Codice della classe di stoccaggio
13 - Non Combustible Solids
Classe di pericolosità dell'acqua (WGK)
WGK 1
Punto d’infiammabilità (°F)
Not applicable
Punto d’infiammabilità (°C)
Not applicable
Certificati d'analisi (COA)
Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Ahmed Ismaeel et al.
Biochimica et biophysica acta. Molecular basis of disease, 1868(1), 166278-166278 (2021-10-04)
The vascular pathology of peripheral artery disease (PAD) encompasses abnormal microvascular architecture and fibrosis in response to ischemia-reperfusion (I/R) cycles. We aimed to investigate the mechanisms by which pathological changes in the microvasculature direct fibrosis in the context of I/R.
Huber Lena et al.
Journal of tissue engineering, 13, 20417314221114423-20417314221114423 (2022-09-27)
Nasal septum defects can currently only be reconstructed using autologous cartilage grafts. In this study, we examine the reconstruction of septal cartilage defects in a rabbit model using porcine decellularized nasal septal cartilage (DNSC) functionalized with recombinant platelet-derived growth factor-BB
Tianrun Liu et al.
Nature communications, 9(1), 3439-3439 (2018-08-29)
Angiogenesis is a hallmark of cancer. However, most malignant solid tumors exhibit robust resistance to current anti-angiogenic therapies that primarily target VEGF pathways. Here we report that endothelial-mesenchymal transformation induces glioblastoma (GBM) resistance to anti-angiogenic therapy by downregulating VEGFR-2 expression
Gesine Paul et al.
The Journal of clinical investigation, 125(3), 1339-1346 (2015-02-18)
BACKGROUND. Recombinant human PDGF-BB (rhPDGF-BB) reduces Parkinsonian symptoms and increases dopamine transporter (DAT) binding in several animal models of Parkinson's disease (PD). Effects of rhPDGF-BB are the result of proliferation of ventricular wall progenitor cells and reversed by blocking mitosis.
Jin-Woo Lee et al.
Journal of hematology & oncology, 14(1), 148-148 (2021-09-18)
Little is known about endogenous inhibitors of angiogenic growth factors. In this study, we identified a novel endogenous anti-angiogenic factor expressed in pericytes and clarified its underlying mechanism and clinical significance. Herein, we found Kai1 knockout mice showed significantly enhanced
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.